MedTech Innovator

MedTech Innovator is a nonprofit global competition and accelerator based in Los Angeles, California, founded in 2013. It focuses on supporting companies in the medical device, digital health, and diagnostic sectors. The organization aims to enhance patient outcomes by fostering the growth of businesses that contribute to the transformation of the healthcare system. Each year, MedTech Innovator showcases 100 companies that align with key themes identified through surveys of industry leaders. The accelerator's diverse portfolio includes firms involved in consumer healthcare, imaging, remote patient monitoring, clinical studies, and workflow optimization, emphasizing its commitment to advancing innovative healthcare solutions.

Paul Grand

Founder and CEO

Ayelet Marom Ph.D

Vice President, Programs

Past deals in Medical

APrevent Medical

Non Equity Assistance in 2024
APrevent Medical Inc. is a medical device company founded in 2014 and headquartered in Taipei, Taiwan, with an additional office in Austria. The company specializes in developing therapeutic medical devices aimed at enhancing the quality of life for patients suffering from speech disorders. APrevent Medical focuses on innovative solutions, including a long-term implant system and a speech conversion platform, designed to provide minimally invasive treatments and support for voice and communication issues. By integrating advanced technologies, the company aims to offer effective interventions that enable patients to improve their speech capabilities and overall communication.

The Shape Sensing Company

Non Equity Assistance in 2024
The Shape Sensing Company specializes in advanced fiber optic 3D guidance technology that enables physicians to navigate medical devices within patient-specific anatomical models. Primarily focused on enhancing endovascular procedures, the company's innovative platform allows vascular surgeons and interventional radiologists to efficiently conduct approximately 2.8 million procedures annually in the United States, utilizing a proprietary 3D guidance workstation and guidewire. This technology not only aims to reduce procedure times and operational costs but also enhances patient outcomes by eliminating reliance on traditional X-ray imaging. Beyond its initial applications in medicine, The Shape Sensing Company is also poised to expand its impact across multiple industries, including aerospace, civil engineering, mining, and energy, through collaborations with various Original Equipment Manufacturer (OEM) partners developing 3D-guided devices.

Flow Medical

Non Equity Assistance in 2024
Flow Medical develops a thrombolysis catheter designed to treat pulmonary embolism. Its catheter improves clot visualization, delivers medication directly to the blockage, and monitors treatment progress in real-time, enabling personalized therapy.

Aurie

Non Equity Assistance in 2024
Founded in 2018, Aurie is a medical device company specializing in reusable urinary catheterization systems. Its flagship product is a portable, battery-operated case that washes, dries, and stores catheters, enabling individuals with mobility or neurological conditions to perform safe and independent urinary care.

CytoVeris

Non Equity Assistance in 2024
CytoVeris develops optical-based technologies that assist surgical oncologists in identifying and removing tumor tissue during cancer resection surgery. Its devices enhance surgeons' ability to achieve clean margins, while its OncoMap system detects molecular signatures unique to cancer cells. Founded by Alan Kersey in Farmington, Connecticut in 2018.

REMEDI

Non Equity Assistance in 2024
REMEDI is a solution provider for radiotherapy and radiography.

SanaHeal

Non Equity Assistance in 2024
SanaHeal develops bioadhesive medical technologies designed for rapid and strong adhesion to wet and irregular tissue surfaces. Their platform features nature-inspired adhesives modeled after barnacles and spider webs, providing instant drying and secure attachment in moist environments.

Astek Diagnostics

Non Equity Assistance in 2024
Astek Diagnostics is a healthcare company that develops precision diagnostic technology aimed at improving the diagnosis and treatment of bacterial infections. The company has created a platform that assists physicians in prescribing the correct antibiotics for patients suffering from bacterial sepsis within one hour. Utilizing a single-use cartridge, Astek Diagnostics' device identifies bacterial infections in urine by measuring the oxygen consumption of bacterial species, significantly reducing the turnaround time for results. This innovative approach not only facilitates timely treatment but also helps combat antibiotic resistance through effective susceptibility testing.

Craif

Non Equity Assistance in 2024
Craif develops innovative devices for early cancer detection using urine tests. Founded in 2018, the company aims to improve cancer survival rates by enabling painless, accurate, and regular diagnosis through its MicroRNA technology.

TYBR Health

Non Equity Assistance in 2024
TYBR Health is a medical device company that develops a sprayable hydrogel to reduce internal scarring after surgery. The hydrogel, derived from natural sources, has shown a 75% reduction in scarring in preclinical studies. It is applied through a steerable device that can be used in both open and minimally invasive procedures, helping surgeons protect healing tissues and improve recovery outcomes. Founded in 2020 by Tim Keane and Alex Smith in Houston, Texas, the company focuses on simplifying postoperative care and enhancing the healing response of internal organs.

NeuSpera Medical

Non Equity Assistance in 2024
NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

iCE Neurosystems

Non Equity Assistance in 2024
iCE Neurosystems is a developer of an advanced neuromonitoring platform aimed at enhancing the diagnosis and treatment of brain injuries. The company combines innovative devices, cutting-edge software, and big-data analytics to deliver real-time insights into brain health. This integration enables healthcare professionals to receive early warnings and guide treatment for patients suffering from brain injuries, particularly in critical care settings. By providing revolutionary insights, iCE Neurosystems enhances the ability of doctors and nurses to diagnose and prevent brain injuries more effectively.

Arsenal Medical

Non Equity Assistance in 2024
Founded in 2005, Arsenal Medical develops innovative polymer-based materials for treating vascular diseases. Its primary products include therapeutic foams for managing acute hemorrhage and AxioCore nanofiber technology for cell integration and tissue regeneration. The company focuses on improving local therapy for injury and disease using conventional biomaterials in unconventional ways.

Nanotis

Non Equity Assistance in 2024
Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices aimed at addressing challenges in infectious disease testing, particularly for influenza. The company manufactures microchip-based devices that allow users to quickly and accurately diagnose illnesses. By providing early diagnosis solutions, Nanotis supports medical professionals in practical healthcare settings, thereby enhancing the efficiency of healthcare delivery and improving patient outcomes.

Acorai

Non Equity Assistance in 2024
Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

Robeaute

Non Equity Assistance in 2024
Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.

AccurKardia

Non Equity Assistance in 2024
AccurKardia is an innovative company specializing in ECG-led diagnostics software. It transforms ECG data into a powerful tool to improve patient outcomes globally, with initial applications in cardiology. The company offers AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for automated, near real-time ECG interpretation. Its AI-driven hyperkalemia detection solution, AK+ Guard™, received FDA Breakthrough Device Designation.

Promedius

Non Equity Assistance in 2024
Founded in 2019, Promedius specializes in developing innovative solutions for the early detection and management of musculoskeletal diseases like osteoporosis. Its flagship product, PROS® CXR:OSTEO, uses AI to analyze chest X-ray images, enabling healthcare providers to identify patients at risk of osteoporosis.

BrainSpace

Non Equity Assistance in 2024
BrainSpace collaborates with physicians, families, financial backers, and other parties with the purpose of eliminating the long-term handicap brought on by brain injury.

HealthTech Connex

Non Equity Assistance in 2024
HealthTech Connex is a brain technology company based in the Health and Technology District. It specializes in translational neuroscience innovations aimed at improving neurological performance and overall health outcomes. The company's technology evaluates an individual's cognitive brain health across various conditions, including brain injuries, neurological diseases, and optimization. This enables mental health professionals to detect cognitive impairments related to mental health issues early. By bridging the gap between laboratory capabilities and real-world applications, HealthTech Connex provides valuable services to care and community sectors globally.

VinBrain

Non Equity Assistance in 2024
VinBrain is a healthcare technology company that specializes in artificial intelligence applications within the medical field, particularly in medical imaging and diagnostics. The company offers DrAidTM Teleradiology, a remote medical imaging solution that facilitates the connection of resources and expertise between hospitals, ensuring patients receive quality diagnostic imaging services anytime and anywhere. VinBrain's platform enhances patient outcomes by identifying and distinguishing various types of cancerous cells and tissues, analyzing medical histories to pinpoint potential risk factors, and automatically generating reports based on healthcare data. Utilizing computer vision and generative AI, the company streamlines radiologists' workflows, providing healthcare providers with valuable insights to improve diagnosis, treatment, and overall patient care, while also enhancing operational efficiency.

Progressive Nuero

Non Equity Assistance in 2024
Progressive Neuro, Inc is a Silicon Prairie Center incubated medical device company dedicated to the development of Progressive Stroke Solutions. Progressive Neuro, Inc is focused on developing a unique portfolio of ischemic stroke devices that provide physicians with treatment options beyond aspiration and traditional thrombectomy.

CancerFree Biotech

Non Equity Assistance in 2024
CancerFree Biotech is a startup focused on personalized cancer treatment, developing circulating tumor cell derived organoid platforms to model cancer and guide therapy. The company cultures and expands circulating tumor cells into organoids to help physicians tailor treatment plans across cancer stages, reducing ineffective drug use. Its E.V.A. technology combines organoid culture with artificial intelligence image recognition to rapidly transform circulating tumor cells into cancer derived organoids for applications in cell therapy, cancer vaccines, and new drug development. The platform supports predicting patient responses to therapies and enables pharmaceutical companies to identify effective treatments, with the goal of improving patient outcomes.

FibriCheck

Non Equity Assistance in 2024
FibriCheck is a medically certified software-as-a-medical-device that detects irregular heart rhythms, including atrial fibrillation, through a smartphone camera. The app operates as a software-only solution on prescription, enabling users to measure cardiac rhythm anywhere and anytime, with data automatically shared with a medical professional to support faster diagnosis and appropriate treatment plans. The company leverages artificial intelligence to locate and track heart rhythm issues and to assist in managing conditions such as high blood pressure and heart failure, aiming to revolutionize cardiovascular care and empower patients to monitor and manage their heart health efficiently.

Invicta Medical

Non Equity Assistance in 2024
Invicta Medical develops innovative medical technologies for advanced sleep apnea treatments. Founded in 2013, the company is headquartered in Santa Clara, California.

Cyted

Non Equity Assistance in 2024
Cyted specializes in digital diagnostic infrastructure, utilizing AI and innovative biomarkers for early disease detection. Its mission is to transform diagnostic methods, aiming for a world where diseases are prevented rather than treated.

KA Imaging

Non Equity Assistance in 2024
KA Imaging designs and manufactures advanced X-ray detectors for medical and industrial applications. Its products include static detectors for pipe inspection, dual-energy detectors for baggage screening, dynamic detectors for engine inspection, and mammography detectors. The company's flagship product, Reveal, is a portable dual-energy subtraction X-ray detector cleared by the FDA, offering improved disease detection capabilities. Founded in 2015, KA Imaging is headquartered in Waterloo, Canada.

Qritive

Non Equity Assistance in 2024
Qritive is a technology company that offers an artificial intelligence-powered diagnostic platform aimed at enhancing the accuracy and efficiency of cancer diagnoses. By utilizing advanced AI and natural language processing, Qritive's solution enables medical professionals to analyze microscopy images alongside patients' medical histories. This innovative approach allows hospitals to streamline their diagnostic processes, ultimately reducing costs and improving patient outcomes. With the rising incidence of cancer, Qritive addresses a critical need in the healthcare sector, equipping doctors with modern tools to aid in timely and precise cancer detection.

Juniper Biomedical

Non Equity Assistance in 2024
Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at addressing pelvic health conditions. The company develops micro-implants that deliver targeted treatment by stimulating specific nerves, allowing for local modulation of innervation to muscles and organs. This innovative approach enables the provision of less invasive, safer, and more effective therapies for various conditions, including incontinence, sexual dysfunction, and chronic pain. By concentrating on precision treatment, Juniper Biomedical seeks to improve patient outcomes and enhance quality of life for individuals suffering from these health issues.

Newrotex

Grant in 2023
Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

Neurava

Grant in 2023
Neurava specializes in developing wearable diagnostic devices for epilepsy patients. Their products monitor health metrics, alert users and healthcare providers to seizures and cardiorespiratory dysfunctions, enabling timely intervention and improved treatment outcomes.

IFPx

Grant in 2023
IFPx develops an implantable patient monitoring device that directly analyzes fluid buildup in the body. This device aims to improve the management of chronic illnesses, initially focusing on heart failure.

Biotome

Non Equity Assistance in 2023
Biotome is a biotechnology research firm focused on developing advanced antibody diagnostic tests. The company specializes in identifying markers that indicate a high risk of stomach cancer, aiming to provide more precise and detailed disease information compared to current screening methods. By leveraging next-generation technology and precision immunology, Biotome's tests are designed to enhance the ability of medical professionals to treat patients effectively.

NXgenPort

Non Equity Assistance in 2023
NXgenPort develops digital health technology for remote monitoring of cancer patients between chemotherapy visits. Its Smart Port device measures cell counts and heart function in vivo, alerting physicians to signs of infection and reducing hospitalizations. This data also improves patient outcomes and provides valuable insights for cancer researchers.

Opticyte

Non Equity Assistance in 2023
Opticyte, Inc. is a medical device company based in Seattle, Washington, specializing in the development of advanced algorithms and optical spectroscopy technology to monitor cellular oxygen levels. Founded in 2016 as a spinoff from the University of Washington, the company is focused on creating its first product, the Cell O2 Monitor, which aims to reduce the risk of organ failure. This innovative noninvasive oximeter measures oxygen levels within cells, enabling early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By providing clinicians with essential data, Opticyte's technology facilitates timely treatment decisions that can prevent multiple organ failure and improve patient outcomes. The company comprises teams with extensive experience in engineering, regulatory affairs, and communications, all dedicated to advancing medical device innovation.

Neurava

Non Equity Assistance in 2023
Neurava specializes in developing wearable diagnostic devices for epilepsy patients. Their products monitor health metrics, alert users and healthcare providers to seizures and cardiorespiratory dysfunctions, enabling timely intervention and improved treatment outcomes.

Covellus

Non Equity Assistance in 2023
Covellus is a medical device company focused on developing innovative platform technology for catheters used in minimally invasive surgeries. The company specializes in manufacturing vascular catheter devices and modular catheter systems, which allow physicians to customize existing devices to meet the specific needs of individual patients. By enhancing the versatility and adaptability of medical devices, Covellus aims to improve treatment outcomes in various medical procedures.

Prana Thoracic

Non Equity Assistance in 2023
Prana Thoracic is a Houston-based medical device company developing tools to enable early diagnosis and minimally invasive treatment of lung cancer. Founded by surgeons, engineers, and entrepreneurs, the company aims to improve outcomes by making it easier to manage suspicious lung nodules and obtain definitive tissue for diagnosis, using tissue-sparing surgical instruments capable of capturing nodules and sealing tissue during minimally invasive procedures.

AMI

Non Equity Assistance in 2023
Founded in Japan in 2015, AMI specializes in manufacturing medical equipment, notably stethoscopes. The company also offers healthcare consulting services, including hospital management and clinical research.

Renovos

Non Equity Assistance in 2023
Renovos is an orthopaedic regenerative medicine company focused on bone healing. It develops synthetic nano clay-based injectable scaffolds and related therapeutics to support research and clinical efforts in faster, safer, and more cost-effective bone repair. The company combines stem cell science with advanced material technologies to deliver regenerative solutions for trauma, injury, disease, and age-related bone deterioration. By offering scaffolds designed for targeted delivery, Renovos aims to accelerate healing, reduce pain, and improve patient recovery, enabling clinicians to pursue more efficient treatment options.

Sparta Biomedical

Non Equity Assistance in 2023
Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

Invenio Imaging

Non Equity Assistance in 2023
Invenio Imaging, Inc. is a privately held company founded in 2012 and based in Santa Clara, California. It specializes in the development of advanced technology for non-destructive microscopic analysis of the molecular composition of tissues and various materials. The company offers a multi-modal coherent Raman scattering microscope aimed at research and development as well as medical applications. Invenio Imaging's innovative platform technology is designed to facilitate intraoperative histology by providing high-resolution imaging that allows for the examination of specimens from multiple sites within a surgical cavity. The company was established based on research conducted by Professor Sunney Xie at Harvard University and has received funding from the National Science Foundation and the National Institutes of Health's Small Business Innovation Research programs.

Veinway

Non Equity Assistance in 2023
VeinWay is a medical device company focused on developing innovative solutions for the treatment of chronic venous occlusions caused by blockage or disease. The firm's primary offering is a specialized catheter designed to recanalize obstructed veins, providing physicians with a dedicated tool to navigate and clear complicated blockages. By facilitating the restoration of blood flow to the heart, VeinWay aims to transform the management of chronic venous disease and improve patient outcomes. The company's technology not only enables medical professionals to cross previously un-crossable obstructions but also aims to reduce the time required for such procedures.

MACH32

Non Equity Assistance in 2023
MACH32 develops medical devices and drug-delivery solutions for pre-hospital and urgent-care trauma treatment. It designs safe, reliable tools that enable healthcare professionals to treat patients in the field while using protective equipment to reduce exposure to infectious aerosols, supporting rapid and safer intervention in emergency situations.

SafeGuard Surgical

Non Equity Assistance in 2023
SafeGuard Surgical is a medical device company focused on improving surgical outcomes and patient safety. It develops innovative, resorbable products designed to enhance colonic anastomotic healing and stability during advanced surgical procedures. These include a resorbable intraluminal stent graft and an extraluminal resorbable graft, along with anvil cap extension arms. By employing these products, SafeGuard aims to reduce surgical complications, lower healthcare costs, and minimize patient recovery time, ultimately preventing mortality and morbidity associated with surgery.

Mirai Medical

Non Equity Assistance in 2023
Mirai Medical is a medical device company focused on developing innovative technologies for cancer therapy. The company specializes in creating devices that improve cancer treatment outcomes and enhance patient experiences. Mirai Medical's proprietary technology allows for the painless endoscopic delivery of electroporation energy, facilitating effective cancer treatment. This approach enables endoscopists to perform pulse field ablation safely and efficiently, significantly advancing the field of cancer therapy.

DasiSimulations

Non Equity Assistance in 2023
DasiSimulations is a company that specializes in providing innovative simulations aimed at enhancing pre-operative preparation for patients with heart disease, particularly those suffering from Structural Heart Disease. Founded in 2019 by Teri Anderson-Sirset and Dr. Dasi, and headquartered in Dublin, Ohio, DasiSimulations focuses on improving patient outcomes and reducing healthcare costs through advanced individualized computational predictive modeling. Utilizing artificial intelligence and proprietary algorithms, the company's technology platform empowers medical professionals to make more informed decisions during transcatheter aortic valve replacement procedures.

Sentante

Non Equity Assistance in 2023
Sentante is a medical technology company specialising in the development of robotic teleoperated systems for endovascular procedures. Their core product enables physicians to perform complex surgeries remotely, reducing their exposure to harmful X-rays and expanding telesurgery capabilities.

Perceptive Medical

Non Equity Assistance in 2023
Perceptive Medical is a developer of advanced medical devices aimed at enhancing blood pressure management in critical care settings, such as the intensive care unit (ICU) and operating room. The company's products are designed to integrate seamlessly into modern clinical workflows, providing healthcare providers with precise tools to address inefficiencies in patient care. By focusing on delivering measurable improvements in blood pressure therapy, Perceptive Medical plays a vital role in optimizing patient outcomes and supporting clinical professionals in their efforts to enhance overall care efficiency.

PanTher Therapeutics

Non Equity Assistance in 2023
PanTher Therapeutics is a biotechnology company developing cancer drug-delivery technologies. Its core platform enables therapeutics to be delivered directly to the tumor site, reducing systemic toxicity and allowing higher drug concentrations at the target while enabling sustained treatment. This approach aims to improve therapeutic efficacy and outcomes for hard-to-treat cancers by maximizing drug exposure at the tumor while limiting exposure to healthy tissue. Headquartered in Cambridge, Massachusetts, PanTher Therapeutics is advancing investigational candidates, including a lead program in pancreatic cancer, to broaden the potential of precision delivery in oncology.

Xcision Medical Systems

Non Equity Assistance in 2023
Xcision Medical Systems develops advanced stereotactic radiotherapy solutions for treating breast cancer. Its radiosurgery device delivers gamma irradiation, enabling a single, non-invasive treatment session instead of weeks-long courses, reducing radiation exposure to surrounding tissues and allowing patients to resume normal lives more quickly.

Endocision

Non Equity Assistance in 2023
Endocision is a medical device company focused on creating innovative minimally-invasive technologies for the diagnosis and treatment of lung diseases. The company specializes in robotic bronchoscopy technologies and a cryo-biopsy platform, which enhance the safety and effectiveness of procedures used by healthcare professionals. Endocision's solutions aim to facilitate the diagnosis and management of conditions such as interstitial lung disease and lung cancer, thereby improving patient outcomes through advanced medical interventions.

Inbrain Neuroelectronics

Non Equity Assistance in 2023
Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

Hypervision Surgical

Non Equity Assistance in 2023
Hypervision Surgical develops an AI-powered hyperspectral imaging platform designed to enhance surgical precision, safety, and speed. The non-contact, non-invasive optical system splits light into multiple spectral bands to provide real-time, data-driven tissue characterization that can be visualized intraoperatively without contrast agents. This approach enables clinicians to assess tissue during procedures, potentially improving accuracy, reducing risk, and supporting decision-making throughout surgery.

ImmersiveTouch

Non Equity Assistance in 2023
ImmersiveTouch Inc., established in Chicago, Illinois in 2005, specializes in developing, installing, and managing virtual reality simulators for medical training and patient engagement. The company's core offering is a high-fidelity immersive surgical simulator, housed within an 'immersive pod', which enables surgeons to interact with realistic 3D computer-generated anatomical models using haptic instrument replicas. This system provides lifelike visual, tactile, and audio sensations, facilitating skill development and pre-operative planning across various medical specialties such as core surgery skills, neurological surgery, spine, and ophthalmology. Additionally, ImmersiveTouch has expanded its offerings to include AI-driven digital surgery platforms, the Ikshana XR platform, which provides clinicians with data insights to enhance decision-making, improve patient outcomes, and optimize surgical resource allocation.

Universal Brain

Non Equity Assistance in 2023
Universal Brain develops individualized mental health treatments based on brain activity. It specializes in neurofeedback therapy algorithms that merge MRI and EEG data using deep learning.

Newrotex

Non Equity Assistance in 2023
Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

Averto Medical

Non Equity Assistance in 2023
Averto Medical specializes in the manufacture of medical devices designed to improve outcomes for patients with gastrointestinal diseases. Their innovative solutions aim to facilitate minimally invasive colorectal tumor removal and other gastrointestinal surgeries, enabling healthcare professionals to provide optimal care.

Knowtex

Non Equity Assistance in 2023
Knowtex is a clinical workflow platform that automates administrative tasks in healthcare. It uses artificial intelligence and voice technology to capture conversations during patient visits, analyze discussions to extract relevant medical information, and generate detailed visit notes with billing code suggestions and order entries. The platform aims to improve organizational efficiency, ensure visits are billed at the appropriate level of service, and streamline documentation by converting medical conversations into accurate records. By reducing manual administrative work, Knowtex helps healthcare professionals save time and maintain thorough, compliant patient documentation.

270Surgical

Non Equity Assistance in 2023
270Surgical Ltd. is a medical device company based in Netanya, Israel, founded in 2016. The company specializes in developing innovative surgical technologies, notably its flagship product, the SurroundScope System. This pioneering laparoscopic camera system features 270-degree wide field of view technology, which significantly enhances visualization during surgeries, thereby reducing the risk of 'off-screen' injuries and improving patient outcomes. The SurroundScope is designed to address common challenges faced in laparoscopic procedures, such as restricted visibility, lens fogging, and obstructions caused by surgical smoke. The system has received FDA clearance and is endorsed by prominent leaders in the field, establishing its credibility and effectiveness in enhancing surgical safety and efficiency.

Purgo Scientific

Non Equity Assistance in 2023
Purgo Scientific is a medical device company focused on developing innovative solutions for targeted therapeutic drug delivery. The firm is working on a localized drug delivery device aimed at addressing the critical issue of biofilm infections in orthopedic surgery. This technology is designed to treat and prevent surgical site infections that can arise from the presence of indwelling orthopedic implants. By enabling precise medicine delivery, Purgo Scientific's device not only seeks to eradicate infections caused by biofilms but also has potential applications in managing pain and oncology-related health issues.

Ankr Health

Non Equity Assistance in 2023
Ankr Health uses AI and telemedicine to automate side effect management in cancer and surgical clinics. Founded in 2022 and is based in San Francisco, CA.

Hertility Health

Non Equity Assistance in 2023
Hertility Health is a women's health company specializing in reproductive healthcare. It offers unique diagnostic testing, expert advice, and educational resources, enabling women to manage their fertility and hormonal health from home.

Nininger Medical

Non Equity Assistance in 2023
Nininger Medical is a medical technology company focused on developing innovative solutions for heart failure treatment. The company is currently working on a transcatheter tricuspid valve replacement device (TTVR) that utilizes proprietary 3D thin film technology. This advanced approach aims to provide effective heart valve therapies, helping to prevent structural heart failure in patients. Nininger Medical has gained recognition for its innovative efforts, recently receiving a Small Business Innovation Research grant from the National Science Foundation, which underscores its commitment to advancing healthcare solutions.

EchoPixel

Non Equity Assistance in 2023
EchoPixel develops advanced medical visualization software. Its flagship product, True 3D Viewer, enables real-time interactive exploration of patient-specific organs and tissues in a virtual reality environment, assisting doctors in identification, evaluation, and dissection of structures. The company also offers educational tools for medical students and intraoperative imaging support for structural heart procedures.

Travera

Non Equity Assistance in 2023
Travera, LLC is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in cancer therapy guidance through its innovative measurement technology, utilizing the Suspended Microchannel Resonator (SMR). This advanced device functions as an extremely sensitive scale that can detect minute changes in the weight of individual cancer cells, specifically measuring the Mass Accumulation Rate (MAR) biomarker. By identifying rapid weight changes in response to cancer drugs, Travera enables oncologists to make informed decisions about which therapies to prescribe, based on the actual responses of patients' tumor cells. The technology is designed to differentiate between natural cell death and drug-induced cell death, providing timely and accurate insights that are critical for effective cancer treatment.

CORIT Medical

Non Equity Assistance in 2023
CORIT Medical is a medical device company based in McLean, VA. It specializes in a Class I single-use surgical device designed to improve breathing during inferior turbinate reduction procedures. The device, which requires no expensive equipment, offers more durable results compared to competing technologies and enables ENTs to perform the procedure in their office, yielding higher reimbursement.

4th Dimension EMR

Non Equity Assistance in 2023
A software company specializing in healthcare solutions. It offers practice management and electronic medical record (EMR) systems designed to facilitate patient information administration and documentation for healthcare practitioners.

Proton Intelligence

Non Equity Assistance in 2023
Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Meacor

Non Equity Assistance in 2022
MeaCor Inc. is a Montreal-based company that specializes in the development of innovative transcatheter devices for the treatment of heart disease, specifically focusing on valvular diseases. The company manufactures a catheter-based medical device designed to repair the mitral and tricuspid valves, utilizing an anchoring catheter system. This approach significantly reduces the risks and trauma associated with traditional surgical methods, thereby enabling effective treatment for patients who are not suitable candidates for conventional surgery, particularly those suffering from mitral valve regurgitation. Through its advancements, MeaCor aims to improve patient outcomes and expand treatment options in the field of cardiovascular health.

Gradient Denervation Technologies

Non Equity Assistance in 2022
Gradient Denervation Technologies develops an endovascular catheter-based medical device designed to treat pulmonary hypertension by reducing pulmonary vascular resistance and improving cardiovascular hemodynamics. Founded in 2019, the company is headquartered in Paris, France.

Epineuron

Non Equity Assistance in 2022
Epineuron Technologies, Inc. is a medical device company based in Hamilton, Canada, established in 2016. It specializes in developing innovative treatment strategies for peripheral nerve injuries through bioelectronic medicine. The company focuses on creating a suite of surgical solutions aimed at enhancing the repair and regeneration of peripheral nerves. Epineuron's flagship product is an electroceutical device that delivers targeted electrical stimulation to accelerate the natural healing processes of injured nerves. By leveraging this technology, Epineuron aims to set a new standard of care in the field of nerve injury treatment, aspiring to become a leader in bioelectronic nerve care.

MicroGEM

Non Equity Assistance in 2022
MicroGEM is a microbiology research company focused on democratizing molecular biology by making complex molecular techniques accessible outside of skilled laboratory environments. The company specializes in an innovative enzymatic approach to nucleic acid extraction, which provides sample preparation suitable for polymerase chain reaction (PCR) analysis. This technology enables clients to develop portable diagnostic devices aimed at managing infectious diseases and advancing personalized medicine applications. By facilitating easier access to molecular tools, MicroGEM aims to enhance the capabilities of various sectors in healthcare and diagnostics.

Ad Vital

Non Equity Assistance in 2022
Ad Vital is a developer of medical lead management and automation software specifically designed for plastic surgeons and aesthetic practices. The company provides a digital marketing tool that assists medical practices in attracting, converting, and retaining patients more efficiently. Its platform features artificial intelligence-powered chatbots and automation software, which help streamline repetitive tasks, enhance patient communication, and optimize operational efficiency. By utilizing Ad Vital's solutions, medical practices can reduce workload and improve overall patient engagement.

SUTUREGARD Medical

Non Equity Assistance in 2022
SUTUREGARD Medical, Inc. is a medical device company based in Portland, Oregon, specializing in the development, manufacturing, and supply of innovative wound closure devices. Founded in 2014, the company offers products designed to simplify the surgical closure of wounds. Its flagship device, SUTUREGARD ISR, facilitates stress-relaxation during the healing process, addressing issues such as skin stretch and reducing tension on surgical wounds. Additionally, the HEMIGARD ARS is an adhesive retention suture device that enhances skin strength, allowing for linear wound closure without the risk of skin tearing. These advanced solutions enable the closure of high-tension and fragile skin wounds with minimal damage, promoting a more efficient and less painful healing experience for patients.

Fluid Biomed

Non Equity Assistance in 2022
Fluid Biomed is a medical device start-up specializing in the development of an innovative implantable dissolving stent aimed at treating brain aneurysms. Founded by a team of neurosurgeons, the company focuses on enhancing patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that gently redirects blood flow to facilitate the healing of weakened blood vessels. This advanced medical device is designed to minimize the need for invasive procedures, allowing physicians to efficiently and effectively treat patients while reducing the risk of stroke. Through its pioneering approach, Fluid Biomed is poised to contribute significantly to the field of neurosurgery and improve the quality of care for individuals with brain aneurysms.

Garwood Medical Devices

Non Equity Assistance in 2022
Garwood Medical Devices, LLC is a Buffalo, New York-based company that develops and manufactures innovative medical devices aimed at combating infections related to prosthetic implants and wound healing. The company specializes in BioPrax, a minimally invasive device designed to target and eliminate biofilm infections on prosthetic knee implants during early intervention procedures. By effectively addressing infection-causing bacteria without necessitating follow-up surgeries, Garwood Medical Devices enables healthcare practitioners to improve treatment outcomes and help patients retain their implants. Originally founded as Enermed, LLC in 2014, the company rebranded to its current name in December 2015, reflecting its commitment to advancing medical technology in the field of infection management.

Digma Medical

Non Equity Assistance in 2022
Digma Medical is a clinical stage medical device company focused on innovative treatments for Type-2 Diabetes and related metabolic disorders, including NASH. Founded in 2013, the company is developing the DiaGone™, a disposable endoscopic device that employs advanced laser technology to target the duodenum, the first section of the small intestine. This device is designed to address insulin resistance, the core issue in these diseases. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to utilize the DiaGone™ to enhance the body's natural ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and improve overall health outcomes.

Bright Uro

Non Equity Assistance in 2022
Bright Uro is an early-stage medical technology company developing a wireless, catheter-free urodynamic monitoring system. This innovative device aims to improve the diagnosis and management of lower urinary tract symptoms by enabling spontaneous voiding in natural settings, providing more accurate and comfortable diagnostic assessments.

Aqua Medical

Non Equity Assistance in 2022
Aqua Medical, Inc. is a medical technology company that specializes in developing vapor-based, endoscopic ablation systems aimed at treating gastrointestinal diseases and preventing gastrointestinal cancers. Founded in 2016 by Virender K. Sharma, the company is headquartered in Santa Ana, California. Its innovative ablation technology utilizes high-temperature water vapor generated by a radiofrequency generator, which is delivered endoscopically through proprietary catheters to various parts of the gastrointestinal tract. This platform enables medical practitioners to perform effective, non-surgical treatments for conditions such as pancreatic cysts and esophageal issues, offering a convenient and efficient alternative to traditional surgical methods.

CardiaCare

Non Equity Assistance in 2022
CardiaCare is a medical device company focused on neuromodulation therapy for atrial fibrillation. Its wearable device provides non-invasive treatment and at-home monitoring, utilizing a closed-loop system and machine learning to deliver personalized peripheral neuromodulation that aims to mediate a cardiovascular antiarrhythmic response, reduce the burden of atrial fibrillation and its precursors, and offer rapid clinical and symptomatic relief.

SafeBeat Rx

Non Equity Assistance in 2022
SafeBeat Rx is a technology company specializing in advanced electrocardiogram solutions aimed at enhancing cardiac care. The company has developed software that facilitates remote patient monitoring, continuous telemetry, and event monitoring, significantly reducing the need for prolonged hospital stays for cardiac patients. By leveraging automated artificial intelligence, SafeBeat Rx's technology allows for safe medication initiation for arrhythmia patients while enabling effective monitoring of cardiac implantable electronic devices. This innovative approach expands access to cardiac care, allowing patients to receive essential services from the comfort of their homes.

Liquet Medical

Non Equity Assistance in 2022
Liquet Medical is a medical device development company specializing in localized drug delivery for treating vascular diseases. Its flagship product, the Versus Catheter, is designed to improve patient outcomes and healthcare sustainability.

Augment Health

Non Equity Assistance in 2022
Augment Health is a company focused on developing noninvasive medical devices and artificial intelligence algorithms to enhance the management of bladder dysfunction, particularly for the 7 million patients affected by neurologic disease or injury. The company's innovative technology allows for monitoring urine levels through a device that can be attached to catheters, providing timely notifications to users or care providers when the catheter reaches capacity. This approach aims to shift bladder diagnostics from clinical settings to patients' homes, addressing the high rate of inconclusive test results associated with traditional in-clinic diagnostics. By enabling better bladder health management, Augment Health seeks to prevent complications such as bladder muscle atrophy, ultimately improving the quality of life for patients.

SymPhysis Medical

Non Equity Assistance in 2022
SymPhysis Medical is focused on developing innovative medical technologies aimed at treating chronic diseases, with a particular emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, is a therapeutic device designed for the home management of malignant pleural effusions (MPE), a common complication in late-stage cancer patients. MPE can lead to severe symptoms such as shortness of breath and chest pain, affecting approximately 15% of cancer patients. The releaze device effectively drains excess fluid from the pleural space, utilizing an active component to improve removal efficiency. This technology not only alleviates debilitating symptoms but also makes indwelling pleural catheter treatments more accessible for patients, significantly contributing to their overall well-being.

Endoron Medical

Non Equity Assistance in 2022
Endoron Medical develops a catheter-based device to secure endografts during endovascular aneurysm repair. The treatment uses a stapling mechanism that mimics hand-sewn suturing by deploying multiple staples around the aortic circumference to achieve transmural attachment of the stent graft to the aortic wall. The device aims to reduce endoleaks and graft migration and to enable treatment of complex abdominal aortic aneurysm anatomies by improving fixation and sealing of the endograft.

Moon Surgical

Non Equity Assistance in 2022
Moon Surgical is a medical device company focused on enhancing minimally invasive surgical procedures through advanced robotics. The company is developing the Maestro System, a surgical robot designed to assist in laparoscopy by improving access to these techniques and optimizing the use of resources in the operating room. This technology provides surgeons with enhanced control and adaptability to various surgical conditions, thereby increasing efficiency and improving patient care. Moon Surgical's devices facilitate the stabilization and automatic positioning of endoscopes, as well as organ retraction, while maintaining the traditional surgical workflow. Through its innovative approach, Moon Surgical aims to transform surgical practices and enhance the overall surgical experience for both surgeons and patients.

Oxford Endovascular

Non Equity Assistance in 2022
Oxford Endovascular develops a neurovascular device to treat brain aneurysms. The device uses origami-inspired engineering with a laser-cut metal alloy that has shape-memory, enabling a catheter-delivered implant to expand into a tiny mesh tube that conforms to the vessel. By diverting blood flow away from the aneurysm, it promotes healing and reduces the risk of rupture.

Corveus Medical

Non Equity Assistance in 2022
Corveus Medical is a medical device company focused on innovative solutions for preventing heart failure. The company is developing a neuromodulation device designed to perform nerve ablation through a catheter-based approach. This minimally invasive technology aims to effectively target and access specific tissues, offering a novel treatment option for heart failure. By addressing both the clinical and economic challenges associated with this condition, Corveus Medical seeks to improve patient outcomes and enhance the overall management of heart failure.

ConKay Medical Systems

Non Equity Assistance in 2022
ConKay Medical Systems is an early-stage medical device company focused on creating innovative solutions for treating valvular regurgitation in patients experiencing progressive heart failure. The company has developed a device that utilizes annular repair technology to address the primary cause of functional regurgitation, preserving the integrity of healthy leaflets to ensure they function as intended. By advancing cardiovascular care, ConKay Medical Systems aims to improve treatment outcomes for patients with this serious condition.

Healthcare X.0 - HealthAssist

Non Equity Assistance in 2022
Healthcare X.0 is an online healthcare platform that provides its clients with digitization solutions. The platform provides its clients with health, vascular, patient, onco, nephro, cardio, wound, tele, patient, and diabetic assist database solutions. Healthcare X.0 was launched in 2013 by and is based in Niedersachsen.

Flosonics Medical

Grant in 2019
Flosonics Medical is a Canadian medical device company founded in 2017, specializing in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. Its flagship product, the FloPatch, is a wearable ultrasound sensor designed to monitor blood flow in patients post-clinical intervention, thereby addressing critical clinical needs. The FloPatch is particularly beneficial for healthcare professionals, including physicians, nurses, and paramedics, operating in various high-pressure environments such as ambulances, emergency departments, operating rooms, and intensive care units. The device is notable for its portability, wireless connectivity with tablets and other medical equipment, and user-friendly functionality, all of which contribute to improved patient care in urgent medical situations. Flosonics Medical, previously known as Ke2 Technologies, rebranded in September 2017.

Forest Devices

Grant in 2019
Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company specializes in developing innovative solutions for stroke detection. Its flagship product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. By enabling pre-hospital providers to accurately assess patients, AlphaStroke facilitates timely triage and enhances decision-making in critical care scenarios, ultimately aiming to reduce treatment delays and improve patient outcomes.

OncoRes Medical

Grant in 2019
OncoRes Medical develops an intraoperative imaging technology designed to assist surgeons in identifying tumors and healthy tissues during surgery. The company, based in Perth, Western Australia, collaborates with leading researchers at the University of Western Australia and breast cancer surgeons to develop this patent-protected technology.

ZKR Orthopedics

Seed Round in 2019
ZKR Orthopedics is focused on developing innovative medical devices and procedures to treat chronic knee pain, particularly caused by Condromalacia Patellae, a condition characterized by the degeneration of cartilage and inflammation beneath the kneecap. Millions of individuals suffer from this ailment, often delaying medical treatment due to the traditionally invasive nature of available solutions, which typically involve major surgery. ZKR's approach offers a minimally invasive option that aims to alleviate pain, restore mobility, and potentially reduce the need for knee replacement surgery. The company, founded by Dr. Jeffrey Halbrecht, has successfully developed prototypes and holds multiple patents for its technology. Currently, ZKR is seeking capital to fund product trials, further advancing its mission to improve patient outcomes in orthopedic care.

Moving Analytics

Seed Round in 2019
Moving Analytics is a telehealth service provider that specializes in cardiovascular prevention programs. Its first product Movn is an end-to-end, integrated program to deliver remote and virtual cardiac rehab. The platform reduces readmissions and empowers the effective and efficient delivery of quality care to patients based on 30+ years of research in remote disease management from Stanford University.

ATRO Medical

Venture Round in 2019
ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of anatomically shaped polymer meniscus implants, specifically the Trammpolin. This innovative prosthesis is designed to replace damaged menisci, restoring their protective function by acting as a joint spacer and shock absorber. The Trammpolin mimics the natural meniscus, facilitating adequate load distribution within the knee joint, which can provide significant relief for osteoarthritis patients suffering from severe pain. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise from a public-private collaboration initiated in 2010 that involved various universities, private companies, and support from the Dutch government. This collaborative effort has been instrumental in the design and development of the Trammpolin prototype.

CoapTech

Seed Round in 2019
CoapTech is an early-stage medical device company based in Baltimore, Maryland, founded in 2016 by Dr. Tropello. The company specializes in researching and manufacturing ultrasound-based solutions for feeding tube placement. Its flagship product, the Point-of-care Ultrasound Magnet Aligned (PUMA-G) System, utilizes a patent-pending technology called Coaptive Ultrasound to enhance safety and reduce healthcare costs. This system employs strong rare-earth magnets for device guidance and real-time, low-cost ultrasound for visual feedback, enabling non-surgical providers to perform procedures such as Percutaneous Ultrasound Gastrostomy (PUG). By eliminating risks associated with traditional methods like organ damage, infections, or cancer from fluoroscopy, CoapTech aims to improve medical care delivery globally.

Subtle Medical

Seed Round in 2019
Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.

toSense

Seed Round in 2019
toSense, Inc. is a healthcare technology company based in San Diego, California, focused on developing innovative solutions for at-home monitoring of chronic illnesses. Incorporated in 2008 and previously known as Perminova, Inc., the company specializes in the CoVa Monitoring System, a body-worn sensor designed for patients with conditions such as congestive heart failure and chronic obstructive pulmonary disease. This device, resembling a necklace, measures vital signs including thoracic impedance, heart rate, and respiration rate, using disposable electrodes to ensure accurate monitoring. The collected data is transmitted via gateways to a web-based system, allowing healthcare professionals to review patient information and detect potential health issues earlier than traditional methods. toSense emphasizes the integration of its hardware and software solutions to address real-world medical challenges effectively. As of March 31, 2020, toSense operates as a subsidiary of Baxter International Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.